Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2 year data on BKZ at #ACR24, and this is a summary of four studies being presented this year at ACR24.
All News
Article
Medication-assisted weight loss has boomed in recent yrs. How does weight loss affect disease activity & PROs in RMDs?
≥5% weight loss, after taking a med, led to better disease activity & QoL
Data may inform RCTs to explore effect of these meds in RMDs
Ab0845 #ACR24 @RheumNow
LTE of deucravacitinib trials in psoriasis. Remarkable & frankly surprising (to me) persistence of benefit Very encouraging for patients who start TYKs, looks like those who respond may have prolonged benefit #ACR24 @RheumNow Abstr#0290 #ACRBest https://t.co/kao4vqpPTQ
Caoilfhionn Connolly
Tweet
#0600
🔬BKZ achieves sustained impact in PsA
➡️ BE OPTIMAL & BE COMPLETE trials:BKZ 160 mg Q4W bDMARD-naïve & TNFi-IR PsA pts
➡️Pain,function,fatigue & skin showed greatest & sustained reductions @ 2 yrs👇
🎯BKZ offers sustained response in 🔑PsA domains
#ACR24 @RheumNow https://t.co/uhzZoOrr3H
Akhil Sood MD
Tweet
Does apremilast have cardiometabolic benefits?
Abstract 0598: In PsA patients, 1-year treatment with apremilast associated w/ ↓ body fat mass, including android fat, and was linked w/ improved disease activity (DAS28-CRP). #ACR24 @RheumNow https://t.co/11n4gQN7Xo
Caoilfhionn Connolly
Tweet
#0588
🔬 Sex Differences in PsA
➡️n=1405, pooled RCT data
♀️49%: Milder PsO (PASI 7.8 v 11.5), higher BMI, longer PsA duration,⬆️ fatigue/pain vs ♂️
♀️worse QoL/functional impairment
♂️More dactylitis (45% v 37%)
🩺 Sex-specific factors matter in PsA
#ACR24 @RheumNow
Caoilfhionn Connolly
Tweet
#0589
🔬Time to Response in PsA Domains: Secukinumab
➡️Post-hoc analyses, n=1366
🔑Median time (wks) to MCID 👇
🔴Systemic inflammation <2
🔴MSK: ~4 wks (enthesitis~12)
🔴Fatigue~7–8
🔴PASI75~8–12; nails ~24
🩺 Rapid MSK & QoL benefits precede skin/nail
#ACR24 @RheumNow https://t.co/WfqkryA1CC
Antoni Chan MD (Prof)
Tweet
Switching vs cycling - which is better? In PsA & axSpA, a real-world analysis shows that switching to IL-17Ai after TNFi discontinuation may lead to similar or better outcomes compared to cycling to another TNFi. Data from the CorEvitas PsA/SpA Registry. Abstr#0585.… https://t.co/AJP4NBjmzr
Caoilfhionn Connolly
Tweet
#0585 🔬PsA/axSpA: TNFi Cycling v IL-17Ai Switch
➡️470 pts: Switchers to IL-17Ai had similar/better outcomes v TNFi cyclers @ 6 mo
➡️PsA: Switchers had improved arthritis/psoriasis(-5.0, p=0.02)
➡️axSpA: Switchers had improved fatigue(-9.4, p=0.01)
#ACR24 @RheumNow
Adela Castro
Tweet
PRO-SPIRIT trial data on 1192 PsA pts showed IL-17Ai seemed better than IL-12/23i and IL-23i improving cDAPSA at 3m and as effective as TNFi and JAKi. No much differences seen at 12m. Abst#0076 #ACR24 @RheumNow https://t.co/dScwsmkDOe
Caoilfhionn Connolly
Tweet
#0584🔬Real-World PsA Study:Tofacitinib
➡️141 pts:47% mono,53% combo;~70% on Rx @ 6mo
➡️Similar ⬆️in disease outcomes (cDAPSA LDA: 31% mono vs 21% combo; MDA ~16%).
➡️No significant differences mono v combo outcomes
🩺Tofa effective in diverse PsA population
#ACR24 @RheumNow
Akhil Sood MD
Tweet
With many treatments for #PsA and #PsO, what are the prescribing trends?
Abstract 0604: TNF inhibitors remain the most common (~60%), but over the past 10 years, IL-17i use rose from 0.2% to 19%, and IL-23i from 0.1% to 39.7%! #ACR24 @RheumNow https://t.co/4TnCAkHfuY
Akhil Sood MD
Tweet
Can multidisciplinary clinics improve quality of care for PsA?
Abstract 0596: Multidisciplinary care in PsA associated with ↓ time to first biologic, ↑ dermatology & nurse visits, and better CV risk assessment. #ACR24 @RheumNow https://t.co/2OnUR6te63
Antoni Chan MD (Prof)
Tweet
The METEOR study reveals distinct clinical features in spondyloarthritis (SpA) patients with vs. without IBD.
Key features of those with IBD:
- Lower male prevalence
- Higher uveitis rates
- Lower psoriasis rates
- More structural damage in SI joints
Mirroring gut… https://t.co/EyBZQ91DDn
Adela Castro
Tweet
🚨Therapeutic target in PsO?
Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO).
- HR-PsO: ⬆️percentage in migratory dendritic cells with elevated expression of CXCR4.
- Migratory effect ⬇️ after selective CXCR4 inhibitor. #ACR24 @ElaineHusniMD… https://t.co/nVoAThUxi1 https://t.co/8d1K3nkttI
Adela Castro
Tweet
🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure:
-Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie
#ACR24 @RheumNow https://t.co/Jc0cdmrVhI
Akhil Sood MD
Tweet
Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease control was linked to improved work productivity, including ↓ work impairment, ↓ presenteeism, and ↓ activity impairment. #ACR24 @RheumNow https://t.co/sZBjJ9lk39
Adela Castro
Tweet
High PBO effect in PsA studies
Abst#0772 from U. of Vienna analyzed PBO arms of PsA trials for bDMARDs and tsDMARDs on ACR response rates at week 12:
💡PBO rates significantly increased over time.
💡Recruitment patterns increasing in geographic areas with less affluent health… https://t.co/wAJnwjYkVe
Caoilfhionn Connolly
Tweet
#0582🔬Challenges in Achieving PsA Disease Control
➡️n=2,093; 18% and 8% achieved minimal, very low disease activity respectively
🔑Higher QoL & monotherapy⬆️success; female sex, fatigue, spine pain⬇️outcomes.
🩺Unmet needs remain in PsA; tailored Rx needed
#ACR24 @RheumNow
Antoni Chan MD (Prof)
Tweet
The rising placebo response rates in PsA trials are linked to global recruiting patterns, with more studies in less affluent countries. Limited access to healthcare may drive this trend, highlighting the need for awareness among stakeholders. Plenary Abstr#0722… https://t.co/FplpSlIamR https://t.co/NIp76IS6TZ
